Back to top
more

TransMedics Group (TMDX)

(Delayed Data from NSDQ)

$138.97 USD

138.97
1,154,928

-4.83 (-3.36%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Reasons to Retain ResMed Stock in Your Portfolio for Now

Strong demand for RMD's market-leading mask portfolio raises investors' optimism.

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.

PBH Stock Might Get a Boost From Focused Brand-Building Efforts

Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.

Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?

Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.

Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?

FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Align Technology Stock Dips on Macroeconomic Issues, FX Headwind

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.

Reasons to Retain STERIS Stock in Your Portfolio for Now

STE's strong prospects in the healthcare business arm bode well for investors.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Should You Continue to Retain PODD Stock in Your Portfolio Now?

Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

TransMedics (TMDX) Is Up 3.16% in One Week: What You Should Know

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

New Launches Support Tandem Diabetes Stock Despite Macro Concerns

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.